https://www.healio.com/news/cardiology/20231013/sotagliflozin-reduces-cv-risk-in-patients-with-lv-hypertrophy-without-high-bp
0
0
10/15/23 at 12:05pm
Organization
Healio
Authors
Patients with left ventricular hypertrophy without hypertension were at increased risk for CV death and HF events compared with the overall SCORED trial cohort, and sotagliflozin effectively reduced risk vs. placebo, a speaker reported.A post hoc analysis of …
Create an account
or login to join the discussion